These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 29121075)

  • 1. Functional evaluation of therapeutic response of HCC827 lung cancer to bevacizumab and erlotinib targeted therapy using dynamic contrast-enhanced and diffusion-weighted MRI.
    Chen YF; Yuan A; Cho KH; Lu YC; Kuo MY; Chen JH; Chang YC
    PLoS One; 2017; 12(11):e0187824. PubMed ID: 29121075
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of bevacizumab in combination with erlotinib on EGFR-mutated non-small cell lung cancer xenograft models with T790M mutation or MET amplification.
    Furugaki K; Fukumura J; Iwai T; Yorozu K; Kurasawa M; Yanagisawa M; Moriya Y; Yamamoto K; Suda K; Mizuuchi H; Mitsudomi T; Harada N
    Int J Cancer; 2016 Feb; 138(4):1024-32. PubMed ID: 26370161
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early effects of low dose bevacizumab treatment assessed by magnetic resonance imaging.
    Gaustad JV; Simonsen TG; Smistad R; Wegner CS; Andersen LM; Rofstad EK
    BMC Cancer; 2015 Nov; 15():900. PubMed ID: 26573613
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Focal Adhesion Kinase Inhibitors in Combination with Erlotinib Demonstrate Enhanced Anti-Tumor Activity in Non-Small Cell Lung Cancer.
    Howe GA; Xiao B; Zhao H; Al-Zahrani KN; Hasim MS; Villeneuve J; Sekhon HS; Goss GD; Sabourin LA; Dimitroulakos J; Addison CL
    PLoS One; 2016; 11(3):e0150567. PubMed ID: 26962872
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical Study of a Combination of Erlotinib and Bevacizumab in Early Stages of Unselected Non-Small Cell Lung Cancer Patient-Derived Xenografts.
    Rolff J; Becker M; Merk J; Hoffmann J; Fichtner I
    Target Oncol; 2016 Aug; 11(4):507-14. PubMed ID: 26817645
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bevacizumab counteracts VEGF-dependent resistance to erlotinib in an EGFR-mutated NSCLC xenograft model.
    Masuda C; Yanagisawa M; Yorozu K; Kurasawa M; Furugaki K; Ishikura N; Iwai T; Sugimoto M; Yamamoto K
    Int J Oncol; 2017 Aug; 51(2):425-434. PubMed ID: 28627678
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer.
    Otsuka K; Hata A; Takeshita J; Okuda C; Kaji R; Masago K; Fujita S; Katakami N
    Cancer Chemother Pharmacol; 2015 Oct; 76(4):835-41. PubMed ID: 26349474
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tyr1068-phosphorylated epidermal growth factor receptor (EGFR) predicts cancer stem cell targeting by erlotinib in preclinical models of wild-type EGFR lung cancer.
    Sette G; Salvati V; Mottolese M; Visca P; Gallo E; Fecchi K; Pilozzi E; Duranti E; Policicchio E; Tartaglia M; Milella M; De Maria R; Eramo A
    Cell Death Dis; 2015 Aug; 6(8):e1850. PubMed ID: 26247735
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low-molecular contrast agent dynamic contrast-enhanced (DCE)-MRI and diffusion-weighted (DW)-MRI in early assessment of bevacizumab treatment in breast cancer xenografts.
    Moestue SA; Huuse EM; Lindholm EM; Bofin A; Engebraaten O; Mælandsmo GM; Akslen LA; Gribbestad IS
    J Magn Reson Imaging; 2013 Nov; 38(5):1043-53. PubMed ID: 23908122
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Src inhibitors act through different mechanisms in Non-Small Cell Lung Cancer models depending on EGFR and RAS mutational status.
    Formisano L; D'Amato V; Servetto A; Brillante S; Raimondo L; Di Mauro C; Marciano R; Orsini RC; Cosconati S; Randazzo A; Parsons SJ; Montuori N; Veneziani BM; De Placido S; Rosa R; Bianco R
    Oncotarget; 2015 Sep; 6(28):26090-103. PubMed ID: 26325669
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Continuous inhibition of epidermal growth factor receptor phosphorylation by erlotinib enhances antitumor activity of chemotherapy in erlotinib-resistant tumor xenografts.
    Iwai T; Moriya Y; Shirane M; Fujimoto-Ouchi K; Mori K
    Oncol Rep; 2012 Apr; 27(4):923-8. PubMed ID: 22209766
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phosphatase and tensin homolog deleted on chromosome 10 degradation induced by NEDD4 promotes acquired erlotinib resistance in non-small-cell lung cancer.
    Sun H; Ma H; Wang J; Xia L; Zhu G; Wang Z; Sun J; Chen Z
    Tumour Biol; 2017 Jul; 39(7):1010428317709639. PubMed ID: 28714370
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of erlotinib and a PARP inhibitor inhibits growth of A2780 tumor xenografts due to increased autophagy.
    Sui H; Shi C; Yan Z; Li H
    Drug Des Devel Ther; 2015; 9():3183-90. PubMed ID: 26124641
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transient PI3K inhibition induces apoptosis and overcomes HGF-mediated resistance to EGFR-TKIs in EGFR mutant lung cancer.
    Donev IS; Wang W; Yamada T; Li Q; Takeuchi S; Matsumoto K; Yamori T; Nishioka Y; Sone S; Yano S
    Clin Cancer Res; 2011 Apr; 17(8):2260-9. PubMed ID: 21220474
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monitoring Tumor Response to Antivascular Therapy Using Non-Contrast Intravoxel Incoherent Motion Diffusion-Weighted MRI.
    Shi C; Liu D; Xiao Z; Zhang D; Liu G; Liu G; Chen H; Luo L
    Cancer Res; 2017 Jul; 77(13):3491-3501. PubMed ID: 28487383
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-small cell lung cancer combination therapy: Hyaluronic acid modified, epidermal growth factor receptor targeted, pH sensitive lipid-polymer hybrid nanoparticles for the delivery of erlotinib plus bevacizumab.
    Pang J; Xing H; Sun Y; Feng S; Wang S
    Biomed Pharmacother; 2020 May; 125():109861. PubMed ID: 32070872
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inter-reader reproducibility of dynamic contrast-enhanced magnetic resonance imaging in patients with non-small cell lung cancer treated with bevacizumab and erlotinib.
    van den Boogaart VE; de Lussanet QG; Houben RM; de Ruysscher D; Groen HJ; Marcus JT; Smit EF; Dingemans AM; Backes WH
    Lung Cancer; 2016 Mar; 93():20-7. PubMed ID: 26898610
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emergence of resistance to tyrosine kinase inhibitors in non-small-cell lung cancer can be delayed by an upfront combination with the HSP90 inhibitor onalespib.
    Courtin A; Smyth T; Hearn K; Saini HK; Thompson NT; Lyons JF; Wallis NG
    Br J Cancer; 2016 Oct; 115(9):1069-1077. PubMed ID: 27673365
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Erlotinib plus bevacizumab as an effective treatment for leptomeningeal metastases from EGFR mutation-positive non-small cell lung cancer.
    Sakata Y; Kawamura K; Shingu N; Ichikado K
    Lung Cancer; 2016 Sep; 99():120-2. PubMed ID: 27565925
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Autophagy Inhibition Overcomes the Antagonistic Effect Between Gefitinib and Cisplatin in Epidermal Growth Factor Receptor Mutant Non--Small-Cell Lung Cancer Cells.
    Liu JT; Li WC; Gao S; Wang F; Li XQ; Yu HQ; Fan LL; Wei W; Wang H; Sun GP
    Clin Lung Cancer; 2015 Sep; 16(5):e55-66. PubMed ID: 25979647
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.